This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Food and Drug Administration Panel Speaks

Peter J. McDonnell, MD

Arch Ophthalmol. 1995;113(7):858-859.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ON OCTOBER 20, 1994, the Ophthalmic Devices Panel of the US Food and Drug Administration (FDA) (hereafter referred to as the Panel) met to consider whether to approve the application of one excimer laser manufacturer for photorefractive keratectomy (PRK) to correct myopia. The Panel consists of ophthalmologists and optometrists representing a spectrum from academia to private practice, plus nonvoting representatives of industry and consumers. The deliberations of the Panel members were followed closely by industry and physicians, as well as Wall Street. The possibility of surgically correcting ametropias, allowing "normal" vision without dependence on corrective lenses, is of great interest to the public, resulting in much attention from the lay press.

In many respects, the task before the Panel was a daunting one. Because the Panel has never given approval to a keratorefractive procedure (such as radial keratotomy or automated lamellar keratectomy), it has established no track record by which . . . [Full Text PDF of this Article]

Author Affiliations
Los Angeles, Calif

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?